Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
The study’s investigators are continuing to monitor overall survival and conduct ongoing patient follow-up.
The overall risk of death from primary myelofibrosis declined by more than 50% after the U.S. FDA approved ruxolitinib.
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting.
Advertisement
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT.
The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length.
BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis.
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Findings from a new study “underscore the limited therapeutic value of luspatercept” in anemia and myelofibrosis.
Those with MF with high molecular and cytogenetic risk do not benefit from higher intensity conditioning before transplant.
Adding navitoclax to ruxolitinib led to durable spleen volume reductions and improved total symptoms in myelofibrosis.
There are several risk factors for thrombosis and major bleeding in patients with myelofibrosis, according to a recent study.
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
A recent case study found evidence of an acquired in utero mutation in monozygotic twins who presented with CALR.
A new prognostic model identified risk factors for reduced survival in patients with myelofibrosis who received ruxolitinib.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726